Inwardly rectifying potassium channel (Kir channel)

Inwardly rectifying potassium (Kir) channels are a diverse family of pore-forming membrane proteins that preferentially conduct potassium ions into the cell at potentials negative to the potassium equilibrium potential. They play a critical role in establishing the resting membrane potential and modulating the excitability of cells in the heart, central nervous system, and endocrine glands (Hibino et al., 2010, Physiological Reviews). By regulating the flow of potassium, these channels influence processes such as cardiac repolarization, neuronal firing rates, and the secretion of hormones like insulin (Nichols et al., 2010, Journal of Physiology). Mutations in the genes encoding Kir channels, such as KCNJ2 or KCNJ11, are associated with various clinical conditions known as channelopathies, including Andersen-Tawil syndrome and neonatal diabetes (StatPearls, Potassium Channels). Pharmacologically, Kir channels are significant therapeutic targets; for instance, ATP-sensitive Kir6.2 channels are the primary targets for sulfonylurea drugs used in the treatment of type 2 diabetes (PubChem, CID 3488). Additionally, specific Kir subtypes are being explored as targets for anti-arrhythmic therapies to manage conditions like atrial fibrillation (PubMed, PMID 25638328).

Other names

KirIRKKCNJ familyInward rectifier potassium channelInwardly rectifying K+ channel

Drugs targeting Kir channels typically function as pore blockers or allosteric modulators. For example, sulfonylureas bind to the associated sulfonylurea receptor (SUR) subunit to close ATP-sensitive Kir6.2 channels, while other agents may block the Kir2.1 or Kir3.1 pores to alter cardiac or neuronal electrical activity (Hibino et al., 2010, Physiological Reviews).